Histogen — Conatus Pharmaceuticals — Merger or Acquisition (January 2020)
26 slides from Histogen's merger presentation, Jan 30, 2020
Slide 1: Corporate Overview
Corporate Overview January 30, 2020 Filings under Rule 425 under the Securities Act of 1933 and deemed filed under Rule 14a-12 of the Securities Exchange Act of 1934, as amended Filing by: Conatus Pharmaceuticals Inc. Subject Company: Conatus Pharmaceuticals Inc. SEC File No.: 001- 36003 Redefining
Slide 2: Cautionary Note Regarding Forward-Looking Statements
Cautionary Note Regarding Forward-Looking Statements This presentation contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended, and are intended to be covered by the safe harbo
Slide 3: Additional Information and Where to Find It
Additional Information and Where to Find It Additional Information and Where to Find It This communication is not intended to and does not constitute an offer to sell or the solicitation of an offer to buy any securities or a solicitation of any vote or approval. This communication may be deemed to
Slide 4: A regenerative therapeutics company with a novel biological platform
A regenerative therapeutics company with a novel biological platform that replaces and regenerates tissues in the body The company is marketing Cell Conditioned Media (CCM) cosmetic skincare products and is in development with three other therapeutic products: HST 001 – Hair Stimulating Complex (HSC
Slide 5: Summary of Key Terms
Summary of Key Terms Combined company value under merger agreement of approximately $135MM CNAT value under the merger agreement of approximately $35MM Structure: Reverse Triangular Merger Ownership: 74/26 split (Histogen / Conatus)* Stock Exchange: NASDAQ Capital Market Board Representation: Histog
Slide 6: Executive Leadership Team
Executive Leadership Team Closed multiple business development transactions valued at over $2.2 billion Led companies through development and approval of multiple prescription drugs in the U.S. and Europe Commercially launched prescription drugs in the U.S. generating net sales of over $1 billion in
Slide 7: Technology Platform
Technology Platform Histogen has developed a production process which is highly scalable and economically viable. All of the derivatives from this single proprietary manufacturing process can be used, creating a spectrum of products for a variety of markets from one core technology: An insoluble hum
Slide 8: Histogen Product Pipeline
Histogen Product Pipeline Preclinical Phase 1 Phase 2 Phase 3 Marketed CCM Cosmetics HST 001 Hair Growth (HSC) HST 002 Dermal Filler (hECM) HST 003 Joint Cartilage (hECM) HST 004 Spinal Disc (hECM) Marketed – Partnered with Allergan-WW Phase 1b -Partnered with Huapont in China HST 005 Wound Healing
Slide 9: Anticipated Regulatory Path for all Assets
Anticipated Regulatory Path for all Assets HST 001 Hair Growth HST 002 Dermal Filler HST 003 Joint Cartilage* 2019 Preclinical Preclinical 2020 2021 2022 2023 2024 Phase 1 Phase 1 Phase 1 Phase 2 Pivotal Phase 2 Phase 3 BLA Phase 3 BLA PMA *Potential for Regenerative Medicine Advanced Therapy design
Slide 10: HSC Hair Growth
HSC Hair Growth A minimally-invasive treatment to promote new hair growth where existing treatments only reduce hair loss
Slide 11: HST - Hair Growth US Market Opportunity
HST 001 - Hair Growth US Market Opportunity Addressable Market: $3.6 billion spent on hair loss, targeting men aged 30 – 491 Nature of Treatment: Minimally invasive HSC injections of 0.1mL throughout thinning area of the scalp, administered by dermatologists and cosmetic surgeons Market Growth: 2% p
Slide 12: HSC Clinical Trial Summary
HSC Clinical Trial Summary Subjects Number Formula Safety Efficacy Pilot Phase 1 Men Investigator-Initiated Phase 1 Women Men Age 34-56 Well tolerated No treatment-related adverse events 26 HSC Serum containing, Serum free Statistical significance at 3 months Hair growth continued over time Serum fr
Slide 13: HST Phase 1b Protocol Summary
HST 001 Phase 1b Protocol Summary Objective: To determine optimal dosing of HSC in male pattern hair loss Enrollment Criteria: 21 men, aged 20-55 Male Pattern Hair Loss identified as Norwood-Hamilton 2A, 3, 3V, 4,& 4A Treatment Regimen: 20 injections of HSC week 0, week 6, & week 12 20 injections of
Slide 14: hECM Fillers
hECM Fillers Human-derived collagen and extracellular matrix dermal fillers for delivering longer-lasting effects for the treatment of facial folds and wrinkles addressing a fast growing global market
Slide 15: HST - Dermal Filler US Market Opportunity
HST 002 - Dermal Filler US Market Opportunity Addressable Market: 1.2 million receiving dermal fillers,10 million considering dermal fillers1 Nature of Treatment: Lower face, cheek, and lip account for ~60% of treatments. Patients receive approximately 1.7 treatments per sitting Market Growth: 7% pe
Slide 16: HST Phase 1 Protocol Summary
HST 002 Phase 1 Protocol Summary Objective: Evaluate an all human extracellular matrix (hECM) as a dermal filler, in direct comparison to Restylane-L in moderate to severe nasolabial folds Enrollment Criteria: 22 subjects, men and women, with moderate to severe nasolabial folds 2 clinical sites Trea
Slide 17: hECM Joint Cartilage
hECM Joint Cartilage Histogen’s human extracellular matrix for regenerating hyaline cartilage for the treatment of articular cartilage defects with a unique malleable scaffold that stimulates the body’s own stem cells.
Slide 18: HST - Joint Cartilage US Market Opportunity
HST 003 - Joint Cartilage US Market Opportunity Addressable Market: 0.2 million receiving joint cartilage repair, 17.5 million considering joint cartilage repair1 Nature of Treatment: Patients receiving arthroscopic microfracture or cartilage transplant treatments due to acute injury and/or osteoart
Slide 19: HST - Preclinical Proof of Concept
HST 003 - Preclinical Proof of Concept In vivo efficacy in rat model Untreated defects (10): extensive fibrotic tissue and no articular cartilage at 6 weeks Treated defects (10): congruent and smooth cartilage regeneration and integration with surrounding cartilage at 6 weeks (O’Driscoll score p<0.0
Slide 20: HST - Phase 1 Protocol
HST 003 - Phase 1 Protocol Objective: Evaluate the safety of hECM paste delivered arthroscopically during microfracture procedure Enrollment Criteria: 12 subjects, men and women, who are candidates for microfracture surgery Recent focal cartilage defects of 2 - 4 cm2 in size in the knee 3 clinical s
Slide 21: Key Clinical/Regulatory Milestones
Key Clinical/Regulatory Milestones HST 001 Hair Growth HST 002 Dermal Filler HST 003 Joint Cartilage Submit IND Amendment Submit IDE Initiate Pilot Trial Initiate Phase 1b Trial Initiate Phase 1 Trial Top-line Data Top-line Data Phase 2 Phase 3 Pivotal Phase 1 Data Q1 Q2 Q3 Q4 2021 Submit IND 2021/2
Slide 22: Financial
Financial A track record of successful funding combined with prudent financial management provides the necessary foundation for growth
Slide 23: Financial Snapshot
Financial Snapshot Histogen has raised approximately $20 million to date through licensing transactions, with potential for an additional $10.5 million in future milestone payments under these licenses. Company has No Secured Debt Proposed NASDAQ Ticker: HSTO Cash on hand and receivables at closing
Slide 24: Conatus and Histogen - A Compelling Business Combination
Conatus and Histogen - A Compelling Business Combination Validated Technology: Demonstrated pre-clinical/clinical POC with HSC and hECM CCM marketed by Allergan in their SkinMedica TNS A+ brand Strategic Pipeline: Targeting high-value markets with novel product candidates Clinical development progra
Slide 25: Questions
Questions
Slide 26: Redefining Regenerative Medicine Corporate Overview
Redefining Regenerative Medicine Corporate Overview January 30, 2020
Conatus Pharmaceuticals — Merger or Acquisition (January 2020) on 6ix